Notice type: 3rd Party Publications
Problem Or Issue:
Important Safety Information from Intercept Pharma Ltd regarding Ocaliva (obeticholic acid): New contraindication for the treatment of primary biliary cholangitis (PBC)
in patients with decompensated liver cirrhosis or a history of prior hepatic decompensation
Important Safety Information – Ocaliva (obeticholic acid)